Insider Selling: Utah Medical Products, Inc. (UTMD) Director Sells 1,529 Shares of Stock

Utah Medical Products, Inc. (NASDAQ:UTMD) Director Ernst G. Hoyer sold 1,529 shares of Utah Medical Products stock in a transaction on Friday, February 9th. The shares were sold at an average price of $88.08, for a total value of $134,674.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Shares of Utah Medical Products, Inc. (NASDAQ UTMD) traded up $1.30 on Tuesday, reaching $87.35. The company’s stock had a trading volume of 12,900 shares, compared to its average volume of 12,314. The company has a market cap of $320.16, a price-to-earnings ratio of 38.14 and a beta of 0.77. Utah Medical Products, Inc. has a 1 year low of $58.50 and a 1 year high of $94.00.

Utah Medical Products (NASDAQ:UTMD) last released its earnings results on Tuesday, January 30th. The medical instruments supplier reported $0.95 earnings per share (EPS) for the quarter. The company had revenue of $10.20 million during the quarter. Utah Medical Products had a return on equity of 18.92% and a net margin of 20.54%.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. grew its holdings in Utah Medical Products by 2.0% during the fourth quarter. BlackRock Inc. now owns 161,775 shares of the medical instruments supplier’s stock valued at $13,168,000 after purchasing an additional 3,164 shares during the period. Wells Fargo & Company MN lifted its position in shares of Utah Medical Products by 4.4% during the fourth quarter. Wells Fargo & Company MN now owns 28,464 shares of the medical instruments supplier’s stock worth $2,317,000 after acquiring an additional 1,210 shares in the last quarter. Bailard Inc. purchased a new stake in shares of Utah Medical Products during the fourth quarter worth $816,000. SG Americas Securities LLC purchased a new stake in shares of Utah Medical Products during the fourth quarter worth $189,000. Finally, Strs Ohio lifted its position in shares of Utah Medical Products by 55.6% during the fourth quarter. Strs Ohio now owns 4,200 shares of the medical instruments supplier’s stock worth $341,000 after acquiring an additional 1,500 shares in the last quarter. 66.39% of the stock is owned by institutional investors and hedge funds.

Separately, BidaskClub upgraded Utah Medical Products from a “hold” rating to a “buy” rating in a research report on Wednesday, December 6th.

COPYRIGHT VIOLATION WARNING: “Insider Selling: Utah Medical Products, Inc. (UTMD) Director Sells 1,529 Shares of Stock” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/13/insider-selling-utah-medical-products-inc-utmd-director-sells-1529-shares-of-stock.html.

About Utah Medical Products

Utah Medical Products, Inc (UTMD) is engaged in the business of producing medical devices that are disposable and for hospital use. The Company’s product categories include labor and delivery/obstetrics, including fetal monitoring accessories, Vacuum-Assisted Delivery Systems (VAD), and other labor and delivery tools; neonatal intensive care, including DISPOSA-HOOD, DELTRAN PLUS and GESCO; gynecology/urology/electrosurgery, including LETZ System, FINESSE+ Generator, EPITOME, PATHFINDER PLUS, HOLMIUM LASER FIBRES, LIBERTY System, ENDOCURETTE, TVUS/HSG-Cath and LUMIN, and blood pressure monitoring, including DELTRAN Disposable Pressure Transducer (DPT), and pressure monitoring accessories, components and other molded parts.

Receive News & Ratings for Utah Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Utah Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply